Malkhaz Mizandari

Dr. Malkhaz Mizandari

Tbilisi State Medical University, Tbilisi, Georgia
orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2021 in Academic Radiology
Verified
Journal Article
Closed access
PKPedram Keshavarz
Pedram Keshavarz
FYFereshteh Yazdanpanah
Fereshteh Yazdanpanah
FRFaranak Rafiee
Faranak Rafiee
MMMalkhaz Mizandari
Malkhaz Mizandari

1 January 2018 in Journal of Cancer
Verified
Journal Article
Open access
MMMalkhaz Mizandari
Malkhaz Mizandari
JKJ Kumar
J Kumar
MPM Pai
M Pai
Tinatin ChikovaniTinatin Chikovani
Tinatin Chikovani
TAT Azrumelashvili
T Azrumelashvili
NHN Habib
N Habib
Background: Malignant biliary and/or pancreatic obstruction has often encountered in the advanced stages of periampullary and cholangicarcinomas. HabibTM Radiofrequency (RF) ablation has been successfully used in the management of various cancers of liver and pancreas. Percutaneous HPB probe (EMcision Ltd, London, UK) is a new addition to this class of tools. It is an endoluminal Radiofrequency (RF) catheter which works on the principle of ablation and induces coagulative necrosis to recanalize the obstructed duct. The aim of this study is to address the technical details of canalization, feasibilities and outcomes of percutaneous endo-luminal Radiofrequency (RF) catheter in patients with unresectable malignancy with obstructed bile and pancreatic duct (PD).

1 November 2021 in European Journal of Radiology
Verified
Journal Article
Closed access
PKPedram Keshavarz
Pedram Keshavarz
TATamta Azrumelashvili
Tamta Azrumelashvili
FYFereshteh Yazdanpanah
Fereshteh Yazdanpanah
SNSeyed Faraz Nejati
Seyed Faraz Nejati
FSFaranak Ebrahimian Sadabad
Faranak Ebrahimian Sadabad
MMMalkhaz Mizandari
Malkhaz Mizandari

5 July 2017 in CardioVascular and Interventional Radiology
Verified
Journal Article
Closed access
PDF file
MMMalkhaz Mizandari
Malkhaz Mizandari
TAT. Azrumelashvili
T. Azrumelashvili
JKJ. Kumar
J. Kumar
NHN. Habib
N. Habib

30 July 2022 in Tomography
Verified
Journal Article
Open access
PDF file
Pedram KeshavarzPedram Keshavarz
Pedram Keshavarz
FYFereshteh Yazdanpanah
Fereshteh Yazdanpanah
MEMaryam Emad
Maryam Emad
AHAzadeh Hajati
Azadeh Hajati
SNSeyed Faraz Nejati
Seyed Faraz Nejati
SRSteven S. Raman
Steven S. Raman
We reviewed the reported imaging findings of myocarditis in the literature following COVID-19 vaccination on cardiac imaging by a literature search in online databases, including Scopus, Medline (PubMed), Web of Science, Embase (Elsevier), and Google Scholar. In total, 532 cases of myocarditis after COVID-19 vaccination were reported (462, 86.8% men and 70, 13.2% women, age range 12 to 80) with the following distribution: Pfizer-BioNTech: 367 (69%), Moderna: 137 (25.8%), AstraZeneca: 12 (2.3%), Janssen/Johnson & Johnson: 6 (1.1%), COVAXIN: 1 (0.1%), and unknown mRNA vaccine: 9 (1.7%). The distribution of patients receiving vaccine dosage was investigated. On cardiac MR Imaging, late intravenous gadolinium enhancement (LGE) was observed mainly in the epicardial/subepicardial segments (90.8%, 318 of 350 enhancing segments), with the dominance of inferolateral segment and inferior walls. Pericardial effusion was reported in 13.1% of cases. The vast majority of patients (94%, 500 of 532) were discharged from the hospital except for 4 (0.7%) cases. Post-COVID-19 myocarditis was most commonly reported in symptomatic men after the second or third dose, with CMRI findings including LGE in 90.8% of inferior and inferolateral epicardial/subepicardial segments. Most cases were self-limited.

7 April 2021 in Abdominal Radiology
Verified
Journal Article
Closed access
PDF file
MMMalkhaz Mizandari
Malkhaz Mizandari
PKPedram Keshavarz
Pedram Keshavarz
TATamta Azrumelashvili
Tamta Azrumelashvili
FYFereshteh Yazdanpanah
Fereshteh Yazdanpanah
ELElnaz Lorzadeh
Elnaz Lorzadeh
FSFaranak Ebrahimian Sadabad
Faranak Ebrahimian Sadabad